|
1
|
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ,
Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et
al: Ewing sarcoma: Current management and future approaches through
collaboration. J Clin Oncol. 33:3036–3046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
The WHO Classification of Tumours
Editorial Board, . WHO Classification of Tumours: Soft Tissue and
Bone Tumours. 3.5th edition. International Agency for Research on
Cancer; Lyon: 2020
|
|
3
|
Szuhai K, Ijszenga M, de Jong D,
Karseladze A, Tanke HJ and Hogendoorn PC: The NFATc2 gene is
involved in a novel cloned translocation in a Ewing sarcoma variant
that couples its function in immunology to oncology. Clin Cancer
Res. 15:2259–2268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshida KI, Machado I, Motoi T,
Parafioriti A, Lacambra M, Ichikawa H, Kawai A, Antonescu CR and
Yoshida A: NKX3-1 is a useful immunohistochemical marker of
EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma. Am J Surg
Pathol. 44:719–728. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charville GW, Wang WL, Ingram DR, Roy A,
Thomas D, Patel RM, Hornick JL, van de Rijn M and Lazar AJ: EWSR1
fusion proteins mediate PAX7 expression in ewing sarcoma. Mod
Pathol. 30:1312–1320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toki S, Wakai S, Sekimizu M, Mori T,
Ichikawa H, Kawai A and Yoshida A: PAX7 Immunohistochemical
evaluation of ewing sarcoma and other small round cell tumours.
Histopathology. 73:645–652. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang GY, Thomas DG, Davis JL, Ng T, Patel
RM, Harms PW, Betz BL, Schuetze SM, McHugh JB, Horvai AE, et al:
EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic
findings in a rare aggressive primary bone or soft tissue tumor. Am
J Surg Pathol. 43:1112–1122. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perret R, Escuriol J, Velasco V, Mayeur L,
Soubeyran I, Delfour C, Aubert S, Polivka M, Karanian M, Meurgey A,
et al: NFATc2-rearranged sarcomas: Clinicopathologic, molecular,
and cytogenetic study of 7 cases with evidence of AGGRECAN as a
novel diagnostic marker. Mod Pathol. 33:1930–1944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sadri N, Barroeta J, Pack SD, Abdullaev Z,
Chatterjee B, Puthiyaveettil R, Brooks JS, Barr FG and Zhang PJ:
Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.
Virchows Arch. 465:233–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lipper S and Kahn LB: Case report 235.
Ewing-like adamantinoma of the left radial head and neck. Skeletal
Radiol. 10:61–66. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Makise N, Yoshida K, Iijima T, Yoshida A,
Ushiku T and Ishida T: Skeletal EWSR1-NFATC2 sarcoma previously
diagnosed as ewing-like adamantinoma: A case report and literature
review emphasizing its unique radiological features. Pathol Int.
71:614–620. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seligson ND, Maradiaga RD, Stets CM,
Katzenstein HM, Millis SZ, Rogers A, Hays JL and Chen JL:
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas
identifies the mTOR pathway as a potential therapeutic target. NPJ
Prec Oncol. 5:432021. View Article : Google Scholar
|
|
13
|
Watson S, Perrin V, Guillemot D, Reynaud
S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer
F, Bouvet M, et al: Transcriptomic definition of molecular
subgroups of small round cell sarcomas. J Pathol. 245:29–40. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaheen M, Wurtz LD, Brocken EG and Warmke
LM: EWSR1: NFATC2-rearranged sarcoma in bone-case report and review
of the literature. Hum Pathol. 30:3006802022.
|
|
15
|
Diaz-Perez JA, Nielsen GP, Antonescu C,
Taylor MS, Lozano-Calderon SA and Rosenberg AE: EWSR1/FUS-NFATc2
rearranged round cell sarcoma: Clinicopathological series of 4
cases and literature review. Hum Pathol. 90:45–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bode-Lesniewska B, Fritz C, Exner GU,
Wagner U and Fuchs B: EWSR1-NFATC2 and FUS-NFATC2
gene fusion-associated mesenchymal tumors: Clinicopathologic
correlation and literature review. Sarcoma. 2019:93863902019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuda Y, Zhang L, Meyers P, Tap WD, Healey
JH and Antonescu CR: The clinical heterogeneity of round cell
sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on
clinical features and outcome. Genes Chromosomes Cancer.
59:525–534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gouda MA, Zarzour MA, Vaporciyan AA,
Kairemo K, Chuang HH and Subbiah V: Activity of pazopanib in
EWSR1-NFATC2 translocation associated bone sarcoma.
Oncoscience. 10:44–53. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kosemehmetoglu K, Rekhi B, Erdem ZB,
Yildiz AE and Comunoglu N: Clinicopathological features of three
rare EWSR1::NFATC2 sarcomas of bone and soft tissues. Int J
Surg Pathol. 32:1275–1285. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawai A, Araki N, Sugiura H, Ueda T,
Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T,
et al: Trabectedin monotherapy after standard chemotherapy versus
best supportive care in patients with advanced,
translocation-related sarcoma: A randomized, open-label, phase 2
study. Lancet Oncol. 16:406–416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawaguchi K, Nakano K, Urasaki T, Fukuda
N, Taira S, Ono M, Tomomatsu J, Nishizawa M, Ae K, Matsumoto S and
Takahashi S: Retrospective analysis of trabectedin therapy for soft
tissue sarcoma. In Vivo. 33:1609–1614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kobayashi H, Iwata S, Wakamatsu T,
Hayakawa K, Yonemoto T, Wasa J, Oka H, Ueda T and Tanaka S:
Efficacy and safety of trabectedin for patients with unresectable
and relapsed soft-tissue sarcoma in Japan: A Japanese
musculoskeletal oncology group study. Cancer. 126:1253–1263. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Machado I, Llombart-Bosch A, Charville GW,
Navarro S, Domínguez Franjo MP, Bridge JA and Linos K: Sarcomas
with EWSR1::Non-ETS fusion (EWSR1::NFATC2 and EWSR1::PATZ1). Surg
Pathol Clin. 17:31–35. 2024. View Article : Google Scholar : PubMed/NCBI
|
